Biomarkers and treatment methods for traumatic brain injury-associated impairments
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorAmy Kathleen Wagner
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a TNFα inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.
Claims20
1-59. (canceled)
A method of treating a traumatic brain injury (TBI), or treating or reducing the risk of a TBI-associated impairment, in a subject, comprising administering to the subject an interleukin-7 (IL-7) or an IL-7 agonist, and/or a TNFα inhibitor.
A method for identifying a subject who has sustained TBI as likely to respond to a treatment for a TBI-associated impairment, the method comprising:
- (a) determining the level of a biomarker in a sample obtained from the subject;
- (b) comparing the level of the biomarker to a reference level of the biomarker;
- and
- (c) identifying the subject as likely to respond to the treatment based on the comparison.
A method for treating a TBI-associated impairment in a subject, comprising:
- (a) determining the levels of sTNFR and the level of IL-7 in at least two samples obtained from the subject;
- (b) assigning trajectory group memberships to the subject by assessing the IL-7 and sTNFRI levels of the subject in relation to group-based trajectory analyses derived from a population with TBI;
- and
- (c-i) treating the subject with an IL-7 or an IL-7 agonist if the subject is assigned a low IL-7 trajectory group membership and a low sTNFR trajectory group membership,
- (c-ii) treating the subject with an IL-7 or an IL-7 agonist and a TNFα inhibitor if the subject is assigned a low IL-7 trajectory group membership and a high sTNFR trajectory group membership;
- or
- (c-iii) treating the subject with a TNFα inhibitor if the subject is assigned a high IL-7 trajectory group membership and a high sTNFR trajectory group membership.
Dependencies are inferred from the claim text.